Drug Profile
IMA 101
Alternative Names: ACTolog™; CD8+-T-cells-Immatics N.V.; IMA-101Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Immatics US
- Developer Immatics US; University of Texas M. D. Anderson Cancer Center
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, Infusion)
- 22 Sep 2021 Immatics and the University of Texas MD Anderson Cancer Center completes phase I ACTolog trial in Solid tumours in USA (IV) in September 2021 (NCT02876510)